Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen…
$VRDN Data NOV 9th for VRDN-008! https://t.co/YFPIJ1TSXq https://t.co/eGtV8HYDCQ
$VRDN "We are highly encouraged by the strength of Lumvoa's early launch in TED, which has exceeded expectations," said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. "These strong early results are a testament to Lumvoa's compelling clinical…
$VRDN big ER! https://t.co/UhlZJySaxH https://t.co/j09kM90E4J
$VRDN 26 holla! https://t.co/plKwDuedoU https://t.co/j09kM90E4J
$VRDN great so far! 26.28 Gap fill next! https://t.co/QwzIozOlCc https://t.co/KWumam0KNN
$VRDN 25 next level! https://t.co/E1VEdBrEkk https://t.co/VYJ4xeZnw1
17 analysts rate VRDN Buy on consensus.
Consensus price target: $36.75 (+23.32% upside from $29.80)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Tousignant Jennifer Chief Legal Officer | Aug 19, 2026 | Sale | 10,000 | $245K |
| Fairmount Funds Management LLC director, 10 percent owner: | May 11, 2026 | Purchase | 1,176,470 | $20M |
| Tousignant Jennifer Chief Legal Officer | Dec 31, 2025 | Sale | 2,272 | $70.8K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $70.85M | +23359.93% | $-342.6M |
| 2024 | $302K | -3.82% | $-269.95M |
| 2023 | $314K | -82.28% | $-237.73M |
Stock data for VRDN: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics